Group 1 - The core viewpoint of the articles highlights that under the backdrop of increasing health demands from residents, traditional Chinese medicine companies are expanding their development space through innovative research and development [1][2] - Recently, Jia Ying Pharmaceutical signed research and development cooperation agreements with several institutions, aiming to deepen involvement in multiple innovative and generic drug projects [1] - The cooperation includes the technology transfer of the chemical drug Bilastine tablets and the joint development of high-end generic drug projects JH003 and JH004, targeting areas such as hyperuricemia/gout and heart failure [1] Group 2 - This collaboration is a significant implementation of Jia Ying Pharmaceutical's "4+4" strategy, focusing on new drug research and new product introduction as core strategic elements [2] - The company aims to build a product matrix that integrates traditional Chinese medicine innovation with the field of chemical drug generics, leveraging its "Keya" brand advantages in traditional Chinese medicine [2] - Future plans include enhancing the penetration of core categories in hospitals, OTC, and new retail channels, transitioning the "Keya" brand from product output to health solution provision [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 按照相关法律法规的规定，上市公司证券虚假陈述，给投资人造成的投资损失，应当负赔偿责任。 陈宇霞律师在此提醒，凡在2024年10月01日至2025年04月25日之间买入嘉应制药，且在2025年04月26日 之后继续持有或卖出亏损的投资者，均有权向嘉应制药索赔相关投资损失。以上索赔条件仅代表陈宇霞 律师的观点，不作为任何投资决策和买卖建议，最终以法院认定的索赔条件为准。 参加股票索赔的股民需准备一下材料； 1、股票交易对账单（如对账单上未显示完整的身份证号码，需另外打印股东信息表；对账期间从第一 次买入至完全卖出（或打印对账单之日） 2025年08月4日，广东嘉应制药（维权）股份有限公司发布《关于公司及相关责任人收到<行政处罚事 先告知书>的公告》。因嘉应制药涉嫌信息披露违法违规，广东证监局拟决定对其给予行政处罚。 违法事实 广东证监局经调查认定，嘉应制药存在如下违法事实： 嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称药聚能）的实际控制人，药聚能构成嘉应制 药的关联方。2024年10月至 2025年1月期间，因药聚能存在短期资金需求，嘉应制药的子公司嘉应制 ...

Group 1 - The core issue involves Guangdong Jiaying Pharmaceutical Co., Ltd. facing administrative penalties from the China Securities Regulatory Commission for failing to disclose related party transactions [1] - The company’s subsidiary, Hunan Jiaying, provided short-term loans to a related party, Hunan Yaojuneng Pharmaceutical Co., Ltd., controlled by the chairman, amounting to 219.99 million yuan, which is 28.83% of the company's latest audited net assets [1] - The related party transactions were not properly reviewed or disclosed until the 2024 annual report, violating relevant securities laws [1] Group 2 - The Guangdong Securities Regulatory Bureau plans to impose a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical [1] - Chairman Li Neng is to receive a warning and a fine of 1.6 million yuan, while other executives, including General Manager You Yongping and former CFO Shi Junping, will also face fines [1]

000558 天府文旅 B004 000826 启迪环境 B001 000998 隆平高科 B001 001236 弘业期货 A07 001314 亿道信息 A06 001324 长青科技 A06 002037 保利联合 A06 002198 嘉应制药 A07 002219 新里程 B001 002330 得利斯 B007 002408 齐翔腾达 B003 002424 贵州百灵 A07 002600 领益智造 B007 002629 仁智股份 A07 002634 棒杰股份 A07 002716 湖南白银 A06 002775 文科股份 B004 002799 环球印务 A07 002921 联诚精密 A07 002940 昂利康 B004 002951 金时科技 A06 300691 联合光电 A06 301632 广东建科 A08 600009 上海机场 A08 600031 三一重工 A08 600104 上汽集团 A08 600166 福田汽车 B003 600507 方大特钢 B001 平安基金 B003 融通基金 B007 上银基金 B005 天弘基金 B006 太平基金 B005 信达证券基金 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Group 1: Investigation and Allegations - The company received a notice of investigation from the CSRC on May 28, 2025, due to suspected violations of information disclosure laws [1]. - The investigation revealed that the company's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party to Jiaying Pharmaceutical [2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party without following the required disclosure procedures, totaling 21.999 million yuan, which accounted for 28.83% of the company's latest audited net assets [2]. Group 2: Administrative Penalties - The CSRC plans to impose administrative penalties, including a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical, 1.6 million yuan on Li Neng, 1 million yuan on You Yongping, and 800,000 yuan on Shi Junping [3][4]. - The violations were characterized by a short duration and the company’s timely recovery of non-operating funds, which were disclosed in the 2024 annual report [3]. Group 3: Company Response and Impact - The company believes that the penalties will not lead to significant operational impacts and that it does not fall under the major violations that could trigger mandatory delisting [5]. - Jiaying Pharmaceutical has expressed sincere apologies to investors and committed to enhancing compliance awareness and operational standards [5].

Core Viewpoint - The regulatory authority has imposed penalties on Jiaying Pharmaceutical and its responsible individuals for violations related to information disclosure, specifically concerning the failure to timely disclose a 220 million yuan related party fund borrowing [1][2]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its key personnel received a total fine of 4.9 million yuan due to the failure to disclose 220 million yuan in related party fund borrowing [1][2]. - The Guangdong Securities Regulatory Bureau issued a warning and fines of 1.5 million yuan to Jiaying Pharmaceutical, 1.6 million yuan to Chairman Li Neng, 1 million yuan to General Manager You Yongping, and 800,000 yuan to former CFO Shi Junping [3]. Related Party Transactions - The related party transactions involved Jiaying Pharmaceutical's subsidiary, Jiaying Pharmaceutical (Hunan) Co., Ltd., providing short-term fund borrowing to Hunan Yaoyang, a company controlled by Li Neng, with amounts ranging from 40,000 to 59.99 million yuan [2][3]. - The total amount borrowed in 2024 was 170 million yuan, with an additional 50 million yuan in January 2025, representing 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Management Accountability - Li Neng, as the chairman, is directly responsible for the information disclosure violations, while You Yongping and Shi Junping also hold direct responsibility due to their managerial roles [3]. - The violations occurred shortly after Li Neng's appointment as chairman, indicating potential misconduct in managing company funds [4]. Financial Context of Related Companies - Hunan Yaoyang, controlled by Li Neng, has faced significant financial challenges, with 2024 revenues of 1.165 billion yuan and a net profit of 49.93 million yuan, which are substantially lower compared to competitors [5]. - The company has struggled to secure financing through public offerings, leading to reliance on brand cooperation and franchise models, resulting in only about 4,000 stores compared to competitors with over 10,000 [5].

Core Viewpoint - Jia Ying Pharmaceutical has been fined a total of 4.9 million yuan due to violations of information disclosure laws, which has raised concerns about its governance and financial practices [3][5][6]. Group 1: Regulatory Actions - Jia Ying Pharmaceutical and related responsible persons received a total fine of 4.9 million yuan from the China Securities Regulatory Commission (CSRC) [3]. - The company’s subsidiary, Hunan Jia Ying, provided a total of 220 million yuan in short-term loans to a company controlled by its actual controller, Li Neng, without proper disclosure [3][6]. - The fines include 150,000 yuan for the company, 1.6 million yuan for Li Neng, 1 million yuan for the general manager, and 800,000 yuan for the former financial director [3]. Group 2: Financial Performance - Jia Ying Pharmaceutical has experienced a decline in revenue and net profit over the past two years, with 2024 revenue dropping to 376 million yuan, a decrease of 29.46% year-on-year, and net profit falling to 20.61 million yuan, down 39.94% [14]. - The company reported a significant drop in operating cash flow, turning negative at -11.83 million yuan, a year-on-year decline of 193.73% [16]. - Accounts receivable surged by 40.48% to 132 million yuan, indicating potential liquidity issues [17]. Group 3: Management Changes - The company has seen frequent changes in its executive team, with the resignation of key personnel including the secretary and financial director earlier this year [12]. - Li Neng took over as chairman of Jia Ying Pharmaceutical in August 2024, shortly before the financial misconduct occurred [7][8]. Group 4: Market Reaction - Following the announcement of the regulatory penalties, Jia Ying Pharmaceutical's stock rose by 3.12%, with a total market capitalization of 3.527 billion yuan as of August 1 [1]. - Since June 20, the stock has experienced an upward trend, with a cumulative increase of over 16% [1].

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Summary by Sections Investigation and Allegations - The CSRC issued a notice of investigation due to Jiaying Pharmaceutical's alleged violations of information disclosure laws, specifically related to transactions with its related party, Hunan Yaojuneng Pharmaceutical Co., Ltd. [1][2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to Hunan Yaojuneng, totaling CNY 219.99 million, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Legal Basis and Responsibilities - The actions of Jiaying Pharmaceutical are suspected to violate multiple articles of the Securities Law, including provisions regarding the disclosure of related party transactions [3]. - Key executives, including the chairman and general manager, are identified as directly responsible for the violations, with specific penalties proposed for each individual involved [3][4]. Proposed Penalties - The CSRC plans to impose a warning and a fine of CNY 1.5 million on Jiaying Pharmaceutical, along with individual fines for the chairman (CNY 1.6 million), the general manager (CNY 1 million), and the former financial director (CNY 800,000) [4]. Impact on Operations - Despite the ongoing investigation, Jiaying Pharmaceutical's operations remain normal, and the company asserts that the situation will not significantly impact its business activities [4].

因信息披露违法违规被立案后，监管对嘉应制药（002198）及相关责任人的处罚落地。此前公司在5月 28日晚曾公告，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。（详见本报5月29日报道 本报报道后，002198被立案调查了！） 8月3日晚间，嘉应制药公告，8月1日，公司及相关责任人李能（现任董事长）、游永平（现任董事、总 经理）、史俊平（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（以下简 称《行政处罚书》），因2.2亿元关联资金拆借未及时披露，嘉应制药及相关责任人合计领490万元罚 单。 嘉应制药及相关责任人领490万元罚单 《行政处罚书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称"药聚能"）的实际控 制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需求，嘉 应制药的子公司嘉应制药（湖南）有限公司（以下简称"湖南嘉应"）以月初转出、月末转回的方式，向 药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2 ...

Core Viewpoint - Jia Ying Pharmaceutical (002198) received an administrative penalty notice due to the chairman's misuse of company funds through an affiliated company [1][5] Group 1: Administrative Penalty - The company and responsible individuals, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) on August 1 [1][6] - The CSRC decided to investigate the company for suspected violations of information disclosure laws, leading to the administrative penalty [1][5] Group 2: Fund Misappropriation Details - Li Neng, as the actual controller of Hunan Yao Juneng Pharmaceutical Co., Ltd. (an affiliate), facilitated the transfer of funds from Jia Ying Pharmaceutical to this company, which constituted a non-operational fund transfer [5][6] - From October 2024 to January 2025, Jia Ying Pharmaceutical's subsidiary transferred a total of 21.999 million yuan to the affiliate, representing 28.83% of the company's latest audited net assets [5][6] Group 3: Penalties Imposed - The proposed penalties include a warning and a fine of 1.5 million yuan for Jia Ying Pharmaceutical, a warning and a fine of 1.6 million yuan for Li Neng, a warning and a fine of 1 million yuan for You Yongping, and a warning and a fine of 800,000 yuan for Shi Junping [6][7] Group 4: Background of Li Neng - Li Neng became the chairman of Jia Ying Pharmaceutical in August 2024, just two months before the fund misappropriation occurred [8] - He is also the actual controller of the chain pharmacy Yang Tian He, which has over 4,000 stores nationwide and ranks among the top 20 in China's pharmaceutical retail industry [8] Group 5: Company Overview - Jia Ying Pharmaceutical, established in 2003 and listed in 2007, is a Chinese traditional medicine manufacturer with a portfolio of 70 products [9] - The company has maintained modest financial performance, with total revenues around several hundred million yuan and net profits in the tens of millions [9][10]